Observational study finds blood test achieves high sensitivity and specificity for lung cancer — Evidence Review
Published in npj Precision Oncology, by researchers from Tel Aviv University, JaxBio Technologies, Bnai Zion Medical Center, Sheba Medical Center
Researched by
— the AI search engine for science
Table of Contents
A new, low-cost blood test developed by Tel Aviv University researchers detected over 90% of stage 2–4 lung cancers in an initial study, using DNA methylation patterns instead of sequencing. Related research generally supports the promise of blood-based methylation assays for lung cancer detection, noting similar sensitivities and the potential for cost-effective, scalable screening; however, many studies emphasize the need for larger, more diverse trials to confirm utility, especially for early-stage disease. Read more at the original study source.
- Several recent studies corroborate the high sensitivity and specificity of methylation-based blood tests for lung cancer, although performance for stage I cancer remains a challenge and requires larger validation cohorts 1 2 6 7.
- Some blood-based assays using autoantibody signatures or other biomarkers have shown lower sensitivity, especially for early-stage disease, highlighting the potential advantage of the new methylation-focused approach 4 5.
- Complementing imaging with blood-based assays may improve the accuracy of screening and reduce unnecessary follow-up procedures, a theme echoed in multiple sources that address the limitations of imaging alone and the value of multi-modal screening strategies 2 3 6 7.
Study Overview and Key Findings
Lung cancer is the leading cause of cancer deaths worldwide, and early detection is critical for improving survival rates. While low-dose CT scans are the current standard for screening high-risk groups, they can produce high false-positive rates, leading to invasive procedures and added anxiety. The new study addresses this gap by introducing a cost-effective, sequencing-free blood test that identifies lung cancer–related chemical changes in DNA, offering a potentially scalable tool that could complement imaging.
The research, led by Prof. Yuval Ebenstein and colleagues, focused on DNA methylation patterns in cell-free DNA fragments found in blood. By detecting these chemical signatures using fluorescent labeling and microarray technology, the assay avoids the costs and technical requirements of DNA sequencing, making it more accessible. The method also demonstrated the ability to distinguish between major lung cancer subtypes, suggesting future potential for tumor characterization.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Tel Aviv University, JaxBio Technologies, Bnai Zion Medical Center, Sheba Medical Center |
| Journal Name | npj Precision Oncology |
| Authors | Abed Agbarya, Noa Gilat, Yael Michaeli, Jasline Deek, Assaf Grunwald, Sivan Yogev, Lynne Itelson, Suheil Artul, Rasha Khoury, Michael Peled, Yuval Ebenstein |
| Population | Lung cancer patients and healthy controls |
| Sample Size | n=103 |
| Methods | Observational Study |
| Outcome | Sensitivity and specificity of the blood test for lung cancer |
| Results | Test achieved 93.1% sensitivity and 90.3% specificity for stages 2–4. |
Literature Review: Related Studies
To understand how this new research fits within the broader field, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used:
- lung cancer blood test sensitivity specificity
- non-invasive lung cancer detection methods
- cost-effective cancer screening technologies
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How effective and accurate are blood-based assays for lung cancer detection? | - Methylation-based blood tests (including targeted sequencing and multi-marker panels) achieve sensitivities of 75–93% and specificities of up to 93% for early-stage lung cancer detection 1 2 7. - Autoantibody and other blood biomarker tests vary widely in sensitivity, with some performing poorly for early-stage disease 4 5. |
| What are the limitations of current lung cancer screening methods, and how can new tests help? | - Low-dose CT scans reduce lung cancer mortality but have high false-positive rates, leading to unnecessary follow-up procedures 2 6 13. - Blood-based tests can complement imaging by improving specificity and minimizing invasive diagnostics 2 6 7. |
| How do cost and scalability influence adoption of new cancer screening technologies? | - Sequencing-based methylation tests and traditional liquid biopsies can be expensive and require specialized infrastructure 6 13. - Simpler, lower-cost assays (like fluorescence-based microarrays or targeted panels) can increase accessibility and feasibility for broad screening 2 13. |
| Can blood or breath-based tests distinguish between lung cancer subtypes or track treatment? | - Fragmentome and methylation profiling can help differentiate non-small cell lung cancer subtypes and may track treatment response, though most studies to date are preliminary 7 9. - Breath and blood-based tests show potential for subtype identification, but require further validation 7 9. |
How effective and accurate are blood-based assays for lung cancer detection?
Numerous studies have explored non-invasive blood-based assays, with targeted methylation sequencing and multi-marker panels showing high sensitivity and specificity for lung cancer detection, including early-stage disease 1 2 7. However, performance can vary based on technology and biomarker selection, and autoantibody-based tests have generally demonstrated lower sensitivity, particularly for early-stage tumors 4 5. The new Tel Aviv study's results are consistent with the upper range of sensitivity and specificity reported in the literature, though its performance in stage I disease remains untested.
- Methylation profiling of cell-free DNA is a leading approach for non-invasive lung cancer detection, often outperforming autoantibody and protein biomarker tests 1 2 7.
- The new study's reported 93.1% sensitivity and 90.3% specificity for stages 2–4 are comparable to or slightly higher than previous methylation-based assays 1 2 7.
- Autoantibody-based tests such as EarlyCDT®-Lung have generally shown insufficient sensitivity, particularly for early-stage cancers 4 5.
- Fragmentation analysis of cell-free DNA and machine learning–based classifiers add additional layers of diagnostic accuracy, but require large-scale validation 6 7.
What are the limitations of current lung cancer screening methods, and how can new tests help?
Low-dose CT scans remain the gold standard for lung cancer screening in high-risk populations but are associated with high false-positive rates, leading to unnecessary follow-up scans and invasive procedures 2 6 13. Blood-based assays could serve as a useful adjunct by improving the specificity of screening and informing clinical decisions about which findings warrant further investigation.
- CT-based screening reduces lung cancer mortality but is limited by a substantial false-positive rate, particularly when applied to population-level screening 2 13.
- Integrating blood-based methylation or fragmentome assays with imaging could improve overall diagnostic accuracy and reduce unnecessary interventions 2 6 7.
- Some studies suggest that blood tests may also help differentiate benign from malignant nodules detected on CT, potentially avoiding overtreatment 1.
- The new study supports the idea of using blood tests as a complement, not a replacement, for imaging modalities 13.
How do cost and scalability influence adoption of new cancer screening technologies?
Sequencing-based methylation assays and advanced liquid biopsies are powerful but require significant investment in sequencing technology and computational analysis, limiting their use in resource-constrained settings 6 13. Cost-effective, simple assays that can be performed in standard laboratories may enable broader access to screening, particularly in low- and middle-income countries.
- The new fluorescence-based microarray assay demonstrates potential for low-cost, scalable lung cancer screening ($60 per test, 2–3 day turnaround) 13.
- Prior studies emphasize the need for affordable, rapid, and accurate tests to expand access to cancer screening and reduce overall mortality 2 13 14.
- High costs and infrastructure requirements have limited the widespread implementation of sequencing-based tests in clinical practice 6 13.
- Simpler assays may facilitate integration into existing laboratory workflows and support screening in diverse healthcare settings 13.
Can blood or breath-based tests distinguish between lung cancer subtypes or track treatment?
Advanced blood-based methylation and fragmentome assays, as well as breath-based VOC analysis using nanobiosensors, are being investigated for their ability to distinguish between lung cancer subtypes and monitor disease progression or treatment response 7 9. The new study's preliminary findings suggest potential for both subtype discrimination and real-time treatment monitoring, though larger validation studies are needed.
- Genome-wide cfDNA fragmentation profiles and methylation signatures can differentiate between key lung cancer subtypes (e.g., adenocarcinoma vs. squamous cell carcinoma) 7 9.
- Some breath analyses using advanced sensors can accurately distinguish lung cancer types, but are less established than blood-based methods 9.
- Monitoring changes in methylation or fragmentation patterns may provide a minimally invasive method for assessing response to therapy 7.
- The new study observed methylation pattern shifts in patients responding to treatment, aligning with wider efforts to develop blood-based monitoring tools 7.
Future Research Questions
While initial results of the new blood test are promising, important questions remain. Larger, diverse cohorts are needed to confirm diagnostic performance—especially for early-stage cancers and in real-world screening populations. Additional studies should clarify how these assays compare to, and integrate with, existing diagnostic tools, and whether they can provide information about tumor subtype or treatment response.
| Research Question | Relevance |
|---|---|
| How well do methylation-based blood tests detect stage I lung cancer? | Stage I detection is critical for improving outcomes, but many assays—including the new one—have unproven sensitivity at this stage; larger trials are needed 1 2 7. |
| Can blood-based methylation tests differentiate between benign and malignant lung nodules? | Accurate differentiation could reduce unnecessary procedures after imaging detects suspicious nodules, addressing a key limitation of CT screening 1 13. |
| What is the cost-effectiveness of sequencing-free blood tests for lung cancer in population screening? | Understanding economic and health system impacts is essential for adoption, especially in resource-limited settings 2 13 14. |
| Can blood methylation profiles be used to monitor lung cancer treatment response in real time? | Preliminary data suggest potential for monitoring, but robust, longitudinal studies are required to validate clinical utility 7. |
| How do blood-based methylation and fragmentome tests compare with other non-invasive modalities like breath analysis? | Comparing different non-invasive modalities can identify the optimal approaches for early detection and subtype discrimination in diverse clinical settings 7 8 9. |